6,678 trials
COVID-19 · Venous Thromboembolism · Arterial Thrombosis
Primary: Venous or Arterial Thrombotic Events: Full-dose Anticoagulation Versus Standard-dose Prophylactic Anticoagulation — 4,486; 2,351 Number of wins — p=0.028
Pain
Primary: Quantity of Narcotic Utilized by Patient for Pain in Milligrams at 240 Minutes — 2.66; 3.7 mg
Restless Legs Syndrome · Insomnia · Sleep Disorder
Primary: Actigraphically-Derived Total Sleep Time — 5.03; 11.44; 7.60; 17.96 Minutes
Perforated Appendicitis · Postoperative Infection
Primary: Number of Participants With a Postoperative Intra-abdominal Abscess — 19; 5 Participants
End Stage Renal Disease · Hepatitis C
Primary: Viral Response as Assessed by Number of Participants With Undetectable Hepatitis C RNA — 10 Participants
Atopic Dermatitis · Atopic Dermatitis Eczema
Primary: Psychological General Well-Being Scale (PGWB) — 68.3; 73.7 score on a scale
Migraine
Primary: Resting State Functional Connectivity — 26.2; 23.3 global efficiency percentage — p=0.04
Leiomyoma · Laparoscopy · Uterine Myomectomy
Primary: Hemoglobin Levels Difference Between Pre and Post Surgery. — 0.76; 0.93 g/dL
Pain
Primary: Pain at 12 Hours — 3.9; 3.7 score on a scale
Narcolepsy
Primary: Change in Weekly Rate of Cataplexy Attacks — 0.98 cataplexy attacks per week
Arthritis, Psoriatic
Primary: Percentage of Participants Who Achieved a Clinical State of Minimal Disease Activity (MDA-Joints) Response at Week 16 — 16.0; 33.9 percentage of participants — p=0.0008
Anesthesia
Primary: Time to PACU Discharge — 123; 125 minutes
Heart Failure
Primary: Myocardial Energetic Efficiency — 48621.3; 50035.7; 50301.0; 52942.8 (((mmhg x ml x bpm) /g)/(1/min))
Abuse Potential
Primary: Drug Liking "at This Moment" Visual Analog Scale (VAS) — 54.1; 83.8; 58.9; 58.4 score on a scale
Relapsed Refractory Multiple Myeloma
Primary: Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs) — 46; 45 Participants